Document:

Exhibit 10.1

 

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

This Amended and Restated Investor Rights
Agreement (this “Agreement”) is made and entered into as of November 24, 2020 by and among BJ’s Restaurants,
Inc., a California corporation (the “Company”), SC 2018 Trust LLC, a Delaware limited liability company (“Trust
LLC”), and BJ’s Act III, LLC, a Delaware limited liability company (“BJ’s Act III,” and together
with any transferees of the Securities (as defined in the Purchase Agreement) who agree to become parties to this Agreement, each
an “Investor” and collectively, the “Investors”) (each of the Company, Trust LLC and the
Investors, a “Party” to this Agreement, and collectively, the “Parties”).

RECITALS

WHEREAS, the Company and Trust LLC are parties
to that certain Securities Purchase Agreement, dated as of May 1, 2020 (the “Purchase Agreement”), pursuant
to which Trust LLC became the holder of 375,000 shares of common stock, no par value per share, of the Company (the “Common
Stock” and such shares, the “Common Shares”) and a holder of 875,000 Warrants (as defined in the Common
Share Purchase Warrant);

WHEREAS, in connection with the transactions
contemplated by the Purchase Agreement, Trust LLC and the Company entered into an Investor Rights Agreement, dated as of May 5,
2020 (the “Original IRA”);

WHEREAS, Trust LLC transferred the Common
Shares and Warrants to BJ’s Act III and, in connection therewith, BJ’s Act III entered into a Joinder Agreement, dated
as of May 15, 2020, pursuant to which BJ’s Act III became a party to the Original IRA; and

WHERAS, the Company, Trust LLC and BJ’s
Act III wish to make certain amendments to the Original IRA.

NOW, THEREFORE, in consideration of the foregoing
premises and the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound hereby, agree that the Original IRA shall
be amended and restated as follows:

1.                 
Board Observer Right and Related Agreements.

(a)              
Board Observer

(i)                            
From the date of this Agreement and for so long as no Resignation Event has occurred, the Investors shall have the right
to designate one (1) person (the “Observer”) to serve as an observer at meetings of the Company’s board
of directors (the “Board”) and at meetings of the Governance and Nominating Committee of the Board (the “Nominating
Committee”). Any Observer shall meet the Independence Criteria described in clause (vi) below and shall be designated
by the “Investor Representative” who shall be Ron Shaich or any replacement thereof approved by BJ’s Act
III. Notwithstanding anything in this Agreement to the contrary, the Investor Representative shall not have a right to designate
a person to serve as an Observer or have any Observer attend any meetings of the Board or Nominating Committee for so long as Keith
Pascal or a Suggested Nominee shall be serving as a member of the Board (in either case, such member of the Board, an “Investor
Approved Board Member”); provided, however, that if an Investor Approved Board Member is serving on the Board
but not on the Nominating Committee, the Investor Approved Board Member shall have the right to serve as an Observer with respect
to meetings of the Nominating Committee.

     

     

    

(ii)                         
The Company agrees that it will invite the Observer to attend, in a non-voting observer capacity, all meetings of the Board
and the Nominating Committee for the purposes of permitting the Observer to have current information with respect to the affairs
of the Company and actions taken by the Board or the Nominating Committee. The Observer shall have the right to be heard at any
such meetings, but in no event shall the Observer: (1) be deemed to be a member of the Board or the Nominating Committee; or (2)
have the right to vote on any matter under consideration by the Board or the Nominating Committee or otherwise have any power to
cause the Company to take, or not to take, any action. As a non-voting observer, the Observer will also be provided (concurrently
with delivery to the directors of the Company and members of the Nominating Committee and in the same manner delivery is made to
them) copies of all notices, minutes, consents, and all other materials and information (financial or otherwise) that are provided
to the directors with respect to a meeting or any written consent in lieu of a meeting of the Board or the Nominating Committee
(except to the extent the Observer has been excluded therefrom pursuant to clause (iv) below).

(iii)                       
If a meeting of the Board or the Nominating Committee is conducted via telephone or other electronic medium (e.g.,
videoconference), the Observer may attend such meeting via the same medium; provided, however, that Observer shall not knowingly
provide any other person access to such meeting without the Company's express written consent and, provided further, that
inadvertent access by another person which is promptly remedied upon discovery by the Observer shall not be deemed to breach the
provisions of this Section 1(a)(iii).

(iv)                        
Notwithstanding the foregoing, the Company may exclude the Observer from access to any material or meeting or portion thereof
if the Board or the Nominating Committee determines it is necessary to do so in its reasonable discretion.

(v)                          
good faith (which determination may be made without participation of the Observer), upon advice of the Company’s counsel,
that (1) such exclusion is reasonably necessary to preserve the attorney-client privilege between the Company and such counsel;
provided, however, that any such exclusion shall apply only to such portion of the material or such portion of the meeting
which would be required to preserve such privilege and not to any other portion thereof, or (2) such portion of a meeting is an
executive session limited solely to independent director members of the Board, independent auditors and/or legal counsel, as the
Board may designate, and the Observer (assuming the Observer were a member of the Board for such determination) would not meet
the then-applicable standards for independence adopted by the Securities Exchange Commission, the Nasdaq Stock Market or such other
exchange on which the Company’s securities are then traded.

(vi)                        
The Company shall compensate the Observer in the same amount of all cash retainers, meeting fees and any other cash fees
as if the Observer were an independent member of the Board and a member of the Nominating Committee, as such cash compensation
may be modified from time to time; provided, however, in no event shall the Observer be entitled to any compensation with
respect to any period for which an Investor Approved Board Member has received compensation as an independent member of the Board.
Further, the Company shall reimburse the Observer for all reasonable out-of-pocket expenses incurred by the Observer in connection
with attendance at Board and Nominating Committee meetings. All compensation and reimbursements payable by the Company pursuant
to this Section 1(a)(v) shall be paid to the Observer at the same time as comparable compensation or reimbursement
is paid to the members of the Board.

    	 	2	 

     

    

(vii)                     
Any Observer shall (a) have business, restaurant, marketing, technology, accounting, finance and/or other relevant experiences
or expertise, (b) be reasonably acceptable to the Nominating Committee and the Board, (c) qualify as “independent”
pursuant to Nasdaq Stock Market listing standards (or the standards of such other exchange on which the Company’s securities
are then traded) and satisfy any other criteria applicable to “independent” directors under such listing standards
and under applicable law and the rules and regulations of the Securities and Exchange Commission, (d) have provided the items that
would be required of an independent director pursuant the Company’s normal director intake procedures (including completion
of a standard director and officer questionnaire and completion of a background check), and (e) not serve as a director or officer
of any company that owns, operates or franchises casual dining restaurants; provided that, for purposes of clause (e), such
casual dining restaurants shall not include any fine dining restaurants, any fast casual restaurants or any casual dining restaurants
with fewer than 25 locations and shall not include serving as a director or officer of Trust LLC, BJ’s Act III
or Act III Holdings, LLC or any of its Subsidiaries (clauses (a)-(e), the “Independence Criteria”).

(viii)                   
Within ten (10) business days of his or her name being submitted to the Nominating Committee, the Nominating Committee shall
determine whether a proposed Observer meets the Independence Criteria, and shall promptly notify the Investor Representative of
its decision. In the event the Nominating Committee does not accept a proposed Observer, the Investors shall have the right to
recommend a substitute Observer whose appointment shall be subject to the procedures described above.

(ix)                        
If any Observer is unable or unwilling to serve as an observer, resigns as an observer, is removed as an observer, or for
any other reason fails to serve or is not serving as an observer at any time prior to the occurrence of a Resignation Event, the
Investor Representative shall have the right to designate a person to be a replacement Observer (any such replacement Observer
shall be referred to as a “Replacement Observer”). Any Replacement Observer will be considered and approved
or rejected in accordance with the process specified in Section 1(a)(vii).

(b)              
Resignation Events. The Investors agree that, to the extent any Investor Approved Board Member is not then serving
on the Board, the Observer shall be deemed to no longer be an observer of the Board effective automatically and immediately (i) upon
a Resignation Event or (ii) if at any time following the date of such person’s appointment to the Board such person
no longer meets the Independence Criteria; provided that, in the case of clause (ii), the Investors shall retain the right
to designate a Replacement Observer as the Observer. The Investors shall promptly (and in any event within five (5) business days)
inform the Company in writing if the Investors fail to satisfy the Minimum Ownership Threshold at any time. For the avoidance of
doubt, the Investors shall have no rights under Sections 1 or 4 if a Resignation Event has occurred. For purposes
of this Agreement, a “Resignation Event” means, regardless of actual resignation, if the Investors fail to satisfy
the Minimum Ownership Threshold at any time after the date of this Agreement. For purposes hereof, the “Minimum Ownership
Threshold” shall mean collective beneficial ownership (as determined under Rule 13d-3 promulgated under the Securities
Exchange Act of 1934, as amended (the “Exchange Act”) of the lesser of (i) 187,500 shares of Common Stock (subject
to proportionate adjustment in the event of splits, combinations or reclassifications) or (ii) a number of Common Shares and
shares or rights convertible or exercisable into Common Shares, including the Warrants (whether or not presently convertible or
exercisable) that, in the aggregate, are convertible or exercisable into and/or equal at least 4.25% of the then-outstanding Common
Stock (on an as-converted and as-exercised basis).

    	 	3	 

     

    

(c)              
Consideration of Director Nominee. So long as no Resignation Event has occurred, in the event that Keith Pascal is
no longer serving as a member of the Board, Investor may suggest a replacement member of the Board (a “Suggested Nominee”).
The Nominating Committee shall give good faith consideration to any such Suggested Nominee in the same manner it does for other
proposed nominees; provided, however, neither the Board nor the Nominating Committee shall have any obligation to nominate
a Suggested Nominee for consideration by the stockholders or to appoint any Suggested Nominee to the Board. Any Suggested Nominee
elected or appointed to the Board shall be required to meet the Independence Criteria.

2.                 
[Intentionally omitted].

3.                 
Standstill. Until the occurrence of a Standstill Termination Event, without the prior written consent of the Company,
the Investors will not, nor will they cause or permit any of their respective controlled Affiliates (as defined in the Purchase
Agreement) to:

(a)        effect
or seek, offer or propose (whether publicly or otherwise) to effect, or announce any intention to effect or cause or participate
in or in any way assist, facilitate or encourage any other Person (as defined in the Purchase Agreement) to effect or seek, offer
or propose (whether publicly or otherwise) to effect or participate in, (i) any acquisition of any securities (or beneficial ownership
thereof), or rights or options to acquire any securities (or beneficial ownership thereof), or any assets, indebtedness or businesses
of the Company or its Subsidiaries (as defined in the Purchase Agreement), (ii) any tender or exchange offer, merger or other
business combination involving the Company or its Subsidiaries or assets of the Company or its Subsidiaries constituting a significant
portion of the consolidated assets of the Company and its Subsidiaries, or (iii) any “solicitation” of “proxies”
(as such terms are used in the proxy rules of the Securities and Exchange Commission) or consents to vote any voting securities
of the Company or any of its Subsidiaries;

(b)        form,
join or in any way participate in a “group” (as defined under the Exchange Act) with respect to the Company or otherwise
act in concert with any Person in respect of any such securities;

    	 	4	 

     

    

(c)        otherwise
act, alone or in concert with others, to seek representation on or to control or influence the management, Board or policies of
the Company or to obtain representation on the Board of the Company (other than pursuant to the terms of this Agreement);

(d)        take
any action which would or would reasonably be expected to force the Company to make a public announcement regarding any of the
types of matters set forth in clause (a) above; or

(e)        enter
into any discussions or arrangements with any third party with respect to any of the foregoing;

it being understood that nothing in this Section 3
shall (x) restrict or prohibit any Investor Approved Board Member from taking any action, or refraining from taking any action,
which he or she determines, in his or her reasonable discretion, is necessary to fulfill his or her fiduciary duties as a member
of the Board, (y) restrict the Investors’ acquisition of any Equity Securities (I) paid as dividends or acquired pursuant
to Section 4 of this Agreement, in each case, in accordance with the terms of this Agreement or (II) in connection
with the exercise of the Warrants, or (z) restrict the Investors acquisition of equity or debt securities of the Company or any
of its Subsidiaries, or voting such securities and otherwise exercising its rights and privileges with respect to such securities,
so long as such acquisition, voting or exercise of the rights and privileges, would not constitute a violation of clauses (a)(ii)
and (iii) or (b) through (e) above.

For purposes of this Agreement, a “Standstill
Termination Event” shall mean the later of (A) the third (3rd) anniversary of the date of the Original IRA,
or (B) the occurrence of a Resignation Event; provided, however, that if an Investor Approved Board Member is no longer
serving as a member of the Board for reasons other than such person’s voluntary resignation, incapacity or death (and no
Suggested Nominee is selected as an Investor Approved Board Member promptly following such voluntary resignation, incapacity or
death), the Standstill Termination Event shall be the earlier to occur of clauses (A) and (B) above.

4.                 
Preemptive Rights.

(a)              
Notwithstanding anything contained in Section 3, from and after the Closing Date, for so long as no Resignation
Event has occurred, if the Company makes any public or non-public offering of any New Securities, each Investor shall be afforded
the opportunity to acquire from the Company all or a portion of such Investor’s Preemptive Rights Portion of such New Securities
for the same price as that offered to the other purchasers of such New Securities; provided, that such Investor shall not
be entitled to acquire any New Securities pursuant to this Section 4 to the extent the issuance of such New Securities
to such Investor would require approval of the stockholders of the Company as a result of any such Investor’s status, if
applicable, as an Affiliate of the Company or pursuant to the rules and listing standards of the Nasdaq Stock Exchange, in which
case the Company may consummate the proposed issuance of New Securities to other Persons prior to obtaining approval of the stockholders
of the Company (subject to compliance by the Company with Section 4(e) below).

    	 	5	 

     

    

(b)              
If the Company proposes to offer New Securities, it shall give the Investors written notice of its intention, describing
the anticipated price (or range of anticipated prices), anticipated amount of New Securities and other material terms and timing
upon which the Company proposes to offer the same (including, in the case of a registered public offering and to the extent possible,
a copy of the prospectus included in the registration statement filed with respect to such offering) at least seven (7) business
days prior to such issuance (or, in the case of a registered public offering, at least seven (7) business days prior to the commencement
of such registered public offering) (provided that, to the extent the terms of such offering cannot reasonably be provided seven
(7) business days prior to such issuance, notice of such terms may be given as promptly as reasonably practicable but in any event
prior to such issuance). The Company may provide such notice to the Investors on a confidential basis prior to public disclosure
of such offering. Other than in the case of a registered public offering, the Investor Representative may notify the Company in
writing at any time on or prior to the second (2nd) business day immediately preceding the date of such issuance (or,
if notice of all such terms has not been given prior to the second (2nd) business day immediately preceding the date
of such issuance, at any time prior to such issuance) whether any of the Investors will exercise such preemptive rights and as
to the amount of New Securities the Investors desire to purchase, up to the such Investor’s Preemptive Rights Portion. In
the case of a registered public offering, the Investor Representative shall notify the Company in writing at any time prior to
the second (2nd) business day immediately preceding the date of commencement of such registered public offering (or,
if notice of all such terms has not been given prior to the second (2nd) business day immediately preceding the date
of commencement of such registered public offering, at any time prior to the date of commencement of such registered public offering)
whether any of the Investors will exercise such preemptive rights and as to the amount of New Securities the Investors desire to
purchase, up to such Investor’s Preemptive Rights Portion. Such notice to the Company shall constitute a binding commitment
by the Investors to purchase the amount of New Securities so specified at the price and other terms set forth in the Company’s
notice to it. Subject to receipt of the requisite notice of such issuance by the Company, the failure of the Investor Representative
to respond prior to the time a response is required pursuant to this Section 4(b) shall be deemed to be a waiver of
the Investors’ purchase rights under this Section 4 only with respect to the offering described in the applicable
notice.

(c)              
Each Investor shall purchase the New Securities that it has elected to purchase under this Section 4 concurrently
with the related issuance of such New Securities by the Company (subject to the receipt of any required approvals from any governmental
entity to consummate such purchase by such Investor); provided, that if such related issuance is prior to the twentieth (20th)
business day following the date on which such Investor has notified the Company that it has elected to purchase New Securities
pursuant to this Section 4, then each Investor shall purchase such New Securities within twenty (20) business days
following the date of the related issuance. If the proposed issuance by the Company of securities which gave rise to the exercise
by the Investor of its preemptive rights pursuant to this Section 4 shall be terminated or abandoned by the Company without
the issuance of any securities, then the purchase rights of the Investors pursuant to this Section 4 shall also terminate
as to such proposed issuance by the Company (but not any subsequent or future issuance), and any funds in respect thereof paid
to the Company by the Investors in respect thereof shall be promptly refunded in full.

(d)              
In the case of the offering of securities for consideration in whole or in part other than cash, including securities acquired
in exchange therefor (other than securities by their terms so exchangeable), the consideration other than cash shall be deemed
to be the fair value thereof as reasonably determined by the Board; provided, however, that such fair value as determined
by the Board shall not exceed the aggregate market price of the securities being offered as of the date the Board authorizes the
offering of such securities.

    	 	6	 

     

    

(e)              
In the event that the Investors are not entitled to acquire any New Securities pursuant to this Section 4 because
such issuance would require the Company to obtain stockholder approval in respect of the issuance of such New Securities to the
Investors as a result of any such Investor’s status, if applicable, as an Affiliate of the Company or pursuant to the rules
and listing standards of the Nasdaq Stock Exchange, the Company shall, upon the Investor’s reasonable request delivered to
the Company in writing within seven (7) business days following its receipt of the written notice of such issuance to the Investors
pursuant to this Section 4, at the Investor’s election, (i) consider and discuss in good faith modifications proposed
by the Investors to the terms and conditions of such portion of the New Securities which would otherwise be issued to the Investors
such that the Company would not be required to obtain stockholder approval in respect of the issuance of such New Securities as
so modified; and/or (ii) solely to the extent that stockholder approval is not required in connection with the issuance
of Equity Securities to Persons other than the Investors, use reasonable best efforts to seek stockholder approval in respect of
the issuance of any New Securities to the Investors.

(f)               
If the Investors do not elect to purchase their respective Preemptive Election Share of the New Securities pursuant to this
Section 4, the Company may sell such portion of the New Securities on terms and conditions that are not materially
more favorable in the aggregate to the applicable purchaser(s) than those set forth in the written notice of such offer. If such
sale is not consummated within 120 days of the date upon which the written notice of such offer was given, then no issuance of
such New Securities may be made thereafter by the Company without again offering the same to the Investors in accordance with this
Section 4. The election by any Investor to not exercise its subscription rights under this Section 4 in
any one instance shall not affect its right as to any subsequent proposed issuance.

(g)              
The Company and the Investors shall cooperate in good faith to facilitate the exercise of the Investors’ rights pursuant
to this Section 4, including securing any required approvals or consents.

(h)              
For purposes of this Section 4, the following terms have the following meanings:

(i)                            
“Convertible Securities” means any security convertible into or exchangeable for capital stock of the
Company.

(ii)                         
“Equity Securities” means (A) all capital stock of the Company, (B) all Convertible Securities and (C)
all Options to acquire from the Company shares of such capital stock or such Convertible Stock.

    	 	7	 

     

    

(iii)                       
“Excluded Securities” means (A) any securities issued by the Company as full or partial consideration
in connection with a merger, acquisition, consolidation or purchase of all or substantially all of the securities or assets of
a corporation or other entity; (B) any shares of capital stock or options to purchase shares of capital stock, or other
equity-based awards (including restricted stock units), issued or granted to employees (or prospective employees who have accepted
an offer of employment), directors or consultants (as defined in the Company’s Equity Incentive Plan) of the Company or any
of its Subsidiaries, pursuant to plans that have been approved by a majority of the independent members of the Board or that exist
as of the date of this Agreement; (C) securities issued by the Company upon the exercise, exchange or conversion of any securities
that are exercisable or exchangeable for, or convertible into, shares of capital stock and are outstanding as of the date of this
Agreement, provided that such exercise, exchange or conversion is effected pursuant to the terms of such securities as in effect
on the date of this Agreement; and (D) securities issued by the Company pursuant to any equipment loan or leasing arrangement,
real property leasing arrangement or debt financing from a bank or similar financial institution approved by a majority of the
disinterested members of the Board.

(iv)                        
“New Securities” means all Equity Securities other than: (A) Excluded Securities; (B) shares
of any class of capital stock of the Company issued on a pro rata basis to all holders of such class as a stock dividend or upon
any stock split or other subdivision of shares of capital stock; (C) shares of capital stock of the Company issued as consideration
in connection with an acquisition (approved by the Board) by the Company of assets or capital stock of any Person; (D) shares
of Common Stock issued pursuant to a bona fide public offering, or Convertible Securities or shares of Common Stock issuable upon
exercise or conversion of Convertible Securities issued pursuant to a bona fide public offering, in each case with aggregate proceeds
of at least $10,000,000, (E) shares of Common Stock, Convertible Securities and Options issued to existing or former officers,
directors, employees or consultants of the Company pursuant to any equity incentive plan adopted or approved by the Board from
time to time, including any shares of Common Stock issuable upon exercise of any such Option or settlement or vesting of any award
issued under such plans, (F) rights issued pursuant to a stockholder rights plan, and (G) the issuance of warrants with
indebtedness for purposes of yield enhancement.

(v)                          
“Options” means any options, warrants or other rights to subscribe for, purchase or otherwise acquire
any capital stock of the Company or Convertible Securities.

(vi)                        
“Preemptive Rights Portion” means, with respect to an Investor, the amount of New Securities that each
Investor shall be entitled to purchase in the aggregate determined by multiplying (1) the total number of such offered
shares of New Securities by (2) the quotient of (a) the aggregate number of shares of Common Stock or shares
or rights convertible or exercisable into Common Shares (whether or not presently convertible or exercisable) (on an as-converted
and as-exercised basis) held by such Investor, as of such date, divided by (b) the aggregate number of shares of Common
Stock (on an as-converted and as-exercised basis) outstanding as of such date.

    	 	8	 

     

    

5.                 
Corporate Opportunities. The Company, on behalf of itself and its Subsidiaries, to the fullest extent permitted by
applicable law, (a) acknowledges and affirms that the Investors and their Affiliates and Representatives, including any Observer,
any Investor Approved Board Member or any other members of the Board affiliated with the Investors (the “Investor Group”):
(i) have participated (directly or indirectly) and will continue to participate (directly or indirectly) in direct investments
in corporations, joint ventures, limited liability companies and other entities (“Other Investments”), including
Other Investments engaged in various aspects of businesses similar to those engaged in by the Company and its Subsidiaries (and
related services businesses) that may, are or will be competitive with the Company’s or any of its Subsidiaries’ businesses
or that could be suitable for the Company’s or any of its Subsidiaries’ interests, (ii) have done and may do business
with any client, customer, vendor or lessor of any of the Company or its Affiliates or any other Person with which any of the Company
or its Affiliates has a business relationship, (iii) have interests in, participate with, aid and maintain seats on the board of
directors or similar governing bodies of, or serve as officers of, Other Investments, (iv) may develop or become aware of business
opportunities for Other Investments; and (v) may or will, as a result of or arising from the matters referenced in this Section 5,
the nature of the Investor Group’s businesses and other factors, have conflicts of interest or potential conflicts of interest,
(b) hereby renounces and disclaims any interest or expectancy in any business opportunity (including any Other Investments
or any other opportunities that may arise in connection with the circumstances described in the foregoing clauses (a)(i) through
(a)(v) (each, a “Renounced Business Opportunity”)), (c) acknowledges and affirms that no member of Investor
Group, including any Observer, any Investor Approved Board Member or any other members of the Board affiliated with the Investors,
shall have any obligation to communicate or offer any Renounced Business Opportunity to the Company or any of its Subsidiaries,
and any member of Investor Group may pursue a Renounced Business Opportunity and (d) waives any claim against the Investor Group
and each member thereof. The Company agrees that in the event that the Investor Group or any member thereof acquires knowledge
of a potential transaction or matter which may constitute a corporate opportunity for both (x) the Investor Group and (y) the Company
or its Subsidiaries, a member of the Investor Group shall not have any duty to offer or communicate information regarding such
corporate opportunity to the Company or its Subsidiaries. To the fullest extent permitted by applicable law, the Company hereby
waives any claim against the Investor Group and each member thereof that such member or the Investor Group is liable to the Company
or its stockholders for breach of any fiduciary duty solely by reason of the fact that the Investor Group or such member of the
Investor Group (A) pursues or acquires any corporate opportunity for its own account or the account of any Affiliate or other Person,
(B) directs, recommends, sells, assigns or otherwise transfers such corporate opportunity to another Person or (C) does not
communicate information regarding such corporate opportunity to the Company. Notwithstanding anything to the contrary in the foregoing,
the Company does not renounce its interest in any corporate opportunity if such corporate opportunity was expressly offered or
presented to a Board member or Observer solely in his or her capacity as a member of the Board or as an Observer; provided
that such opportunity has not been separately presented to the Investors, their Affiliates or their respective Representatives.
Notwithstanding anything to the contrary in the foregoing, the Company shall not be prohibited from pursuing any Renounced Business
Opportunity as a result of this Section 5.

6.                 
Access to Information.

(a)              
For so long as no Resignation Event has occurred and subject to the provisions of Section 7, if there is not
at such time an Investor Approved Board Member or any other member of the Board affiliated with the Investors serving on the Board:

(i)                            
the Company shall, and shall cause its Subsidiaries and Representatives to, deliver to the Investor Representative (who
shall have the right to share such information provided by the Company, its Subsidiaries or its Representatives with the Investor
Group) promptly upon reasonable advance notice, all books, records and information, including financial information, and documents
concerning or regarding its businesses, properties and assets and personnel of the Company and its Subsidiaries as may reasonably
be requested by or on behalf of the Investors or their Affiliates.

    	 	9	 

     

    

(ii)                         
the Company shall (and shall cause its Subsidiaries to), upon reasonable prior notice, afford the Investors, their Affiliates
and their respective Representatives reasonable access, during normal business hours, to the Company, its employees, agents, properties,
offices and other facilities, contracts, books and records. The Company shall, and shall cause its Subsidiaries and Representatives
to, cooperate with the Investors, their Affiliates and their Representatives in connection with such investigation and examination,
and the Investors, their Affiliates and their Representatives shall cooperate with the respective Representatives of the Company
and shall use their reasonable best efforts to minimize any disruption to the business.

(b)              
For so long as no Resignation Event has occurred and subject to the provisions of Section 7, any Investor Approved
Board Member or any Observer may, from time to time, share Confidential Information he or she receives with the Investor Group.

7.                 
Confidentiality.

(a)              
The Investors will, and will direct their respective Affiliates and their respective Representatives who actually receive
Confidential Information to, keep confidential any Confidential Information and to use the Confidential Information solely for
the purposes of monitoring, administering or managing the Investors’ investment in the Company made pursuant to this Agreement;
provided that an Investor may disclose Confidential Information (i) to its attorneys, accountants, consultants and financial and
other professional advisors to the extent reasonably necessary to obtain their services in connection with its investment in the
Company, (ii) subject to the provisions of Section 3, to any prospective purchaser of Equity Securities from such Investor
(as long as such prospective purchaser is not an owner, operator or franchisor of casual dining restaurants or an Affiliate of
any such person) agrees in writing to be bound by similar confidentiality or non-disclosure terms as are contained in this Agreement
(with the Company as an express third-party beneficiary of such agreement), (iii) to any Affiliate, partner, member, limited partners,
or related investment fund of such Investor and their Affiliates and their respective Representatives, in each case in the ordinary
course of business (provided that the recipients of such Confidential Information are directed to abide by the confidentiality
and non-disclosure obligations contained herein), (iv) as may be reasonably determined by such Investor to be necessary in connection
with such Investor’s enforcement of its rights in connection with this Agreement or its investment in the Company, or (v)
as may otherwise be required by law or legal, judicial or regulatory process; and provided, further, that (x) any breach of
the confidentiality and use terms herein by any Person to whom such Investor may disclose Confidential Information pursuant to
clauses (i) and (iii) of the preceding proviso shall be attributable to such Investor for purposes of determining such Investor’s
compliance with this Section 7, except those who have entered into a separate confidentiality or non-disclosure agreement
or obligation with the Company and (y) that such Investor takes commercially reasonable steps (at the Company’s sole expense)
to minimize the extent of any required disclosure described in clause (v) of the preceding proviso.

(b)              
For purposes of this Agreement, the following terms shall have the following meanings:

    	 	10	 

     

    

(i)                            
“Confidential Information” means any information (including oral, written and electronic information)
regarding the Company or its Subsidiaries that may be furnished to the Investors, their Affiliates or their Representatives by
or on behalf of the Company pursuant to this Agreement that is non-public, confidential or proprietary in nature, together with
all analyses, compilations, forecasts, studies or other documents prepared by the Investors or their respective Affiliates or Representatives
which contain, are based upon or otherwise reflect such information. “Confidential Information” shall not include
such portions of the Confidential Information that (a) are or become generally available to the public other than as a result
of the Investors’, their Affiliates’ or their Representatives’ disclosure in violation of this Agreement, (b) are
or become available to the Investors, their Affiliates or their Representatives on a non-confidential basis from a source other
than the Company or its Subsidiaries, (c) were already in the Investors’, their Affiliates’ or their Representatives’
possession prior to the date of this Agreement and which were not obtained from the Company or its Subsidiaries or (d) are
independently developed by the Investors, their Affiliates or their Representatives without reference to the Confidential Information.

(ii)                         
“Representatives” means a Person’s directors, members, officers, employees, agents, consultants,
accountants, attorneys or financial advisors and direct or indirect members or partners or Affiliates of the foregoing.

(c)              
The provisions of this Agreement shall supersede that certain Non-Disclosure Agreement, dated April 17, 2020, by and
between the Company and Act III Management, LLC but shall not supersede (i) the existing Non-Disclosure Agreement, dated October 3,
2019, by and among the Company, Noah Elbogen and Trust LLC, or (ii) any similar written agreement with Keith Pascal.

8.                 
Specific Performance. Each of the Investors, on the one hand, and the Company, on the other hand, acknowledges and
agrees that irreparable injury to the other Party hereto would occur in the event any of the provisions of this Agreement were
not performed in accordance with their specific terms or were otherwise breached and that such injury would not be adequately compensable
by the remedies available at law (including the payment of money damages).  It is accordingly agreed that the Investors, on
the one hand, and the Company, on the other hand (in each case, the “Moving Party”), shall each be entitled
to specific enforcement of, and injunctive relief to prevent any violation of, the terms hereof, and the other Party hereto will
not take action, directly or indirectly, in opposition to the Moving Party seeking such relief on the grounds that any other remedy
or relief is available at law or in equity. This Section 8 is not the exclusive remedy for any violation of this Agreement.

    	 	11	 

     

    

9.                 
Section 16 Matters. If the Company becomes a party to a consolidation, merger or other similar transaction, or if
the Company proposes to take or omit to take any other action under Section 4 (including granting to the Investors
or their Affiliates the right to participate in any issuance of New Securities) or otherwise or if there is any event or circumstance
that may result in the Investor Group or any member thereof being deemed to have made a disposition or acquisition of Equity Securities
or derivatives thereof for purposes of Section 16 of the Exchange Act (including the purchase by the Investors of any New
Securities under Section 4 or any awards or grants made to Keith Pascal or any Investor Approved Board Member), and
if an Investor Approved Board Member is serving on the Board at such time or has served on the Board during the preceding six (6)
months (i) the Board or a committee thereof composed solely of two (2) or more “non-employee directors” as defined
in Rule 16b-3 of the Exchange Act will pre-approve such acquisition or disposition of equity securities of the Company or
derivatives thereof for the express purpose of exempting the interests of Investor Group or any member thereof (for the Investors
and/or their Affiliates, to the extent such persons may be deemed to be “directors by deputization”) in such transaction
from Section 16(b) of the Exchange Act pursuant to Rule 16b-3 thereunder and (ii) if the transaction involves (A) a
merger or consolidation to which the Company is a party and the Common Stock is, in whole or in part, converted into or exchanged
for equity securities of a different issuer, (B) a potential acquisition or deemed acquisition, or disposition or deemed disposition,
by Investor Group or any member thereof of equity securities of such other issuer or derivatives thereof and (C) an Affiliate
or other designee of the Investors or their Affiliates will serve on the board of directors (or its equivalent) of such other issuer
pursuant to the terms of an agreement to which the Company is a party (or if the Investors notify the Company of such service a
reasonable time in advance of the closing of such transactions), then if the Company requires that the other issuer pre-approve
any acquisition of equity securities or derivatives thereof for the express purpose of exempting the interests of any director
or officer of the Company or any of its subsidiaries in such transactions from Section 16(b) of the Exchange Act pursuant
to Rule 16b-3 thereunder, the Company shall require that such other issuer pre-approve any such acquisitions of equity securities
or derivatives thereof for the express purpose of exempting the interests of Investor Group or any member thereof (for the Investors
and/or their Affiliates, to the extent such persons may be deemed to be “directors by deputization” of such other issuer)
in such transactions from Section 16(b) of the Exchange Act pursuant to Rule 16b-3 thereunder.

10.             
Securities Laws. Each Investor acknowledges that it is aware, and will advise each of its representatives who are
informed as to the matters that are the subject of this Agreement, that the United States securities laws may prohibit any person
who directly or indirectly has received from an issuer material, non-public information from purchasing or selling securities of
such issuer or from communicating such information to any other person under circumstances in which it is reasonably foreseeable
that such person is likely to purchase or sell such securities.

11.             
Miscellaneous.

    	 	12	 

     

    

(a)              
Governing Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement and interpretation
of this Agreement shall be governed by the internal laws of the State of California, without giving effect to any choice of law
or conflict of law provision or rule (whether of the State of California or any other jurisdictions) that would cause the
application of the laws of any jurisdictions other than the State of California. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in Los Angeles County, California, for the adjudication of any dispute hereunder
or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees
not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court,
that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is
improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit,
action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees
that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be
deemed to limit in any way any right to serve process in any manner permitted by law. TO THE FULLEST EXTENT PERMITTED BY APPLICABLE
LAW, EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION
OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

(b)              
Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each Party and delivered to the other
Parties; provided that a facsimile or .pdf signature shall be considered due execution and shall be binding upon the signatory
thereto with the same force and effect as if the signature were an original, not a facsimile or .pdf signature.

(c)              
Headings. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the
interpretation of, this Agreement.

(d)              
Severability. If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable
by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed
amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such
provision shall not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so modified
continues to express, without material change, the original intentions of the Parties as to the subject matter hereof and the prohibited
nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations
or reciprocal obligations of the Parties or the practical realization of the benefits that would otherwise be conferred upon the
Parties. The Parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with
a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

    	 	13	 

     

    

(e)              
Entire Agreement; Amendment and Waiver. This Agreement and the other Transaction Documents (as defined in the Purchase
Agreement) supersede all other prior oral or written agreements between the Investors, the Company, their Affiliates and Persons
acting on their behalf with respect to the matters discussed herein (including the Original IRA), and this Agreement, the other
Transaction Documents, and the instruments referenced herein and therein contain the entire understanding of the Parties with respect
to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor any
Investor makes any representation, warranty, covenant or undertaking with respect to such matters.  Provisions of this Agreement
may be amended and the observance thereof may be waived (either generally or in a particular instance and either retroactively
or prospectively), only with the written consent of the Company and the Investor Representative. No failure on the part of any
Party to exercise, and no delay in exercising, any right, power or remedy hereunder shall operate as a waiver thereof, nor shall
any single or partial exercise of such right, power or remedy by such Party preclude any other or further exercise thereof or the
exercise of any other right, power or remedy.  All remedies hereunder are cumulative and are not exclusive of any other remedies
provided by law.  Any amendment or waiver effected in accordance with this Section 11(e) shall be binding upon
each Investor and the Company. No such amendment shall be effective to the extent that it applies to less than all of the Investors.
Notwithstanding the foregoing, any Affiliate of Buyer (as defined in the Purchase Agreement) to whom there is a Transfer (as defined
in the Purchase Agreement) of Securities shall have the right to become party to this Agreement as an Investor pursuant to a joinder
to this Agreement.

(f)               
Notices. Any notices, consents, waivers or other communications required or permitted to be given under the terms
of this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally;
(ii) upon delivery, when sent by electronic mail; or (iii) one business day after deposit with an overnight courier
service, in each case properly addressed to the party to receive the same. The addresses and e-mail addresses for such communications
shall be:

	If to the Company:	
        BJ’s Restaurants, Inc.

        7755 Center Avenue

        Huntington Beach, California 92647

        Attention: Greg Levin

        E-mail: glevin@bjsrestaurants.com

         

	with a copy (for informational purposes only) to:	
        

        Elkins Kalt Weintraub Reuben LLC

        10345 W. Olympic Blvd.

        Los Angeles, CA 90064

        Attention: Robert Steinberg, Esq.

        E-mail: rsteinberg@elkinskalt.com

        

 

	If to Trust LLC or to BJ’s Act III:	
        23 Prescott St.

        Brookline, MA 02446

        Attention: Ron Shaich

        E-mail: ronshaich@act3holdings.com

         

	with a copy (for informational purposes only) to:	
        

        Sullivan & Cromwell LLP

        125 Broad St.

        New York, NY 10004

        Attention:    Frank Aquila

                             Audra D. Cohen

        E-mail:         aquilaf@sullcrom.com

                     cohena@sullcrom.com

        

 

    	 	14	 

     

    

	If to the Investor Representative:	
        Ron Shaich

        23 Prescott St.

        Brookline, MA 02446

        E-mail: ronshaich@act3holdings.com

         

	with a copy (for informational purposes only) to:	
        

        Sullivan & Cromwell LLP

        125 Broad St.

        New York, NY 10004

        Attention:   Frank Aquila

                            Audra D. Cohen

        E-mail:        aquilaf@sullcrom.com

                           cohena@sullcrom.com

        

If to an Investor, to its address and e-mail address set forth
on the Schedule of Investors attached hereto, with copies to such Investor’s representatives as set forth on such Schedule
of Investors, with a copy (for informational purposes only) to:

	 	Sullivan & Cromwell LLP
	 	125 Broad St.
	 	New York, NY 10004
	 	Attention:  	Frank Aquila
	 	 	Audra D. Cohen
	 	E-mail:	aquilaf@sullcrom.com
	 	 	cohena@sullcrom.com

 

or to such other address and/or e-mail address and/or to the
attention of such other Person as the recipient Party has specified by written notice given to each other Party five (5) days
prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent,
waiver or other communication, (B) mechanically or electronically generated by the sender’s e-mail containing the time,
date, recipient e-mail address or (C) provided by an overnight courier service shall be rebuttable evidence of personal service,
receipt by e-mail or receipt from an overnight courier service in accordance with clause (i), (ii) or (iii) above, respectively.

(g)              
Successors and Assigns. The terms and conditions of this Agreement shall be binding upon, inure to the benefit of,
and be enforceable by the Parties and their respective successors, heirs, and permitted assigns.  No Party shall assign this
Agreement or any rights or obligations hereunder without, with respect to any Investor, the prior written consent of the Company,
except to an Affiliate of Buyer, and with respect to the Company, the prior written consent of the Investor Representative.

(h)              
No Third Party Beneficiaries. This Agreement is intended solely for the benefit of the Parties and their respective
successors, heirs and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

    	 	15	 

     

    

(i)                
Interpretation; Absence of Presumption.

(i)                            
When a reference is made in this Agreement to an Article, Section, Schedule or Exhibit, such reference shall be to an Article,
Section, Schedule or Exhibit of this Agreement unless otherwise indicated.

(ii)                         
Whenever the words “include,” “includes” or “including” are used in this Agreement,
they shall be deemed to be followed by the words “without limitation.”

(iii)                       
The words “hereof,” “herein,” and “herewith” and words of similar import shall, unless
otherwise stated, be construed to refer to this Agreement as a whole (including all of the Schedules and Exhibits) and not to any
particular provision of this Agreement.

(iv)                        
Unless otherwise specified in this Agreement, the term “dollars” and the symbol “$” mean U.S. dollars
for purposes of this Agreement and all amounts in this Agreement shall be paid in U.S. dollars.

(v)                          
The definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms and
to the masculine as well as to the feminine and neuter genders of such term.

(vi)                        
Any agreement, instrument or statute defined or referred to in this Agreement means such agreement, instrument or statute
as from time to time amended, modified or supplemented, including (in the case of agreements or instruments) by waiver or consent
and (in the case of statutes) by succession of comparable successor statutes.

(vii)                     
Each of the Parties has participated in the drafting and negotiation of this Agreement. If an ambiguity or question of intent
or interpretation arises, this Agreement shall be construed as if it is drafted by each of the Parties, and no presumption or burden
of proof shall arise favoring or disfavoring any Party by virtue of authorship of any of the provisions of this Agreement.

[The remainder of this page intentionally
left blank]

  

    	 	16	 

     

    

IN WITNESS WHEREOF, this Agreement has been duly
executed and delivered by the duly authorized signatories of the Parties as of the date hereof.

 

	 	BJ’S RESTAURANTS, INC.
	 	 
	 	 
	 	By:  /s/ GREGORY S. LEVIN
	 	Name: Gregory S. Levin,
	 	Title:   President & Chief Financial Officer 

 

 

 

[Signature Page to the Amended and Restated Investor Rights Agreement]

 

    	 		 

     

    

IN WITNESS WHEREOF, this Agreement has been duly
executed and delivered by the duly authorized signatories of the Parties as of the date hereof.

 

	 	BJ’S ACT III, LLC
	 	 
	 	 
	 	By:  /s/ RONALD M. SHAICH
	 	Name: Ronald M. Shaich
	 	Title:   Chief Executive Officer
	 	 
	 	 
	 	SC 2018 TRUST LLC
	 	 
	 	 
	 	By:  /s/ RONALD M. SHAICH
	 	Name: Ronald M. Shaich
	 	Title:   Authorized Signatory

 

 

 

[Signature Page to the Amended and Restated Investor Rights Agreement]Exhibit 10.2

AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT

THIS AMENDMENT NO. 1 TO COMMON STOCK PURCHASE
WARRANT (this “Amendment”), dated as of November 24, 2020, is by and between BJ’s Restaurants,
Inc., a California corporation (the “Corporation”), and BJ’s Act III, LLC (together with any assigns,
the “Holder”).

WHEREAS, Holder is the holder of that certain
Common Stock Purchase Warrant, having an initial issuance date of May 5, 2020, granting the Holder the right to acquire up to 875,000
shares of the Common Stock, no par value, of the Corporation (the “Warrant”); and

WHEREAS, Holder and the Corporation wish
to amend the Warrant to provide for certain changes to the anti-dilution rights contained therein.

NOW, THEREFORE, in consideration of the mutual
agreements herein contained, the parties hereto agree as follows:

1.       Defined
Terms. Capitalized terms used but not otherwise defined herein shall have the meanings provided to such terms in the Warrant.

2.       Amendment
to Provisions Regarding Issuances at Less than Fair Market Value. Section 3(c) of the Warrant is hereby amended to include
the following paragraph iii.:

“iii.Notwithstanding anything to the contrary
contained in this Warrant, in no event shall the Exercise Price resulting from the adjustments described in this Section 3(c)
be below $20.00 per share (the “Floor Exercise Price”) (such Floor Exercise Price being subject to proportionate
adjustment in the event of stock splits, dividends or similar events as described in elsewhere in this Section 3).”

3.       Miscellaneous
Provisions.

3.1       Successors.
All the covenants and provisions of this Amendment by or for the benefit of the Corporation or the Holder shall bind and inure
to the benefit of their respective successors and assigns.

3.2       Governing
Law; Jurisdiction. The validity, interpretation, and performance of this Amendment shall be governed in all respects by the
laws of the State of California, in accordance with the provisions of Section 5(d) of the Warrant.

3.3       Counterparts.
This Amendment may be executed in any number of original or facsimile counterparts and each of such counterparts shall for all
purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.

3.4       Effect
of Headings. The section headings herein are for convenience only and are not part of this Amendment and shall not affect the
interpretation thereof.

3.5        Severability.
This Amendment shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect
the validity or enforceability of this Amendment or of any other term or provision hereof. Furthermore, in lieu of any such invalid
or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Amendment a provision
as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.

3.6       No
Other Amendment. Except as specifically set forth in this Amendment, the terms of the Warrant shall remain unchanged and in
full force and effect.

[Signature pages follow]

 

     

     

    

IN WITNESS WHEREOF, the Corporation
and the Holder have caused this Amendment to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

 

	 	BJ’S RESTAURANTS, INC.
	 	 
	 	 
	 	By:  /s/ GREGORY S. LEVIN
	 	Name:  Gregory S. Levin,
	 	Title:    President & Chief Financial Officer 

 

 

 

 

 

 

 

 

[Signature Page to Amendment No.1 to Common Stock Purchase Warrant]

 

     

     

    

IN WITNESS WHEREOF, the Corporation
and the Holder have caused this Amendment to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

 

	 	BJ’S ACT III, LLC
	 	 
	 	 
	 	By:  /s/ RONALD M. SHAICH
	 	Name: Ronald M. Shaich
	 	Title:   Chief Executive Officer

 

 

 

 

 

 

 

[Signature Page to Amendment No.1 to Common Stock Purchase Warrant]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}]]